Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis

Digestive and Liver Disease

Volumn 43, Issue 4, 2011, Pages 286-294

  Galfrascoli, Elena ^a   Piva, Sheila ^a   Cinquini, Michela ^b   Rossi, Antonio ^c   La Verde, Nicla ^a   Bramati, Annalisa ^a   Moretti, Anna ^a   Manazza, Andrea ^d   Damia, Giovanna ^b   Torri, Valter ^b   Muserra, Gaetana ^a   Farina, Gabriella ^a   Garassino, Marina Chiara ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d CERMS   (Italy)

Author keywords

Bevacizumab; Colorectal cancer; Meta analysis; Toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PLACEBO;

ADVANCED CANCER; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOPENIA; LUNG EMBOLISM; META ANALYSIS; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RISK BENEFIT ANALYSIS; STOMACH PERFORATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 79952185124     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2010.10.010     Document Type: Article

References (58)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
2. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
3. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in MCRC: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
4. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
5. Genentech. Bevacizumab prescribing information. [accessed Oct 27, 2008]. http://www.gene.com/gene/products/information/oncology/avastin/.
6. Nalluri S.R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. J Am Med Assoc 2008, 300:2277-2285.
7. Zhu X., Wu S., Dahut W.L., et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against Vascular Endothelial Growth Factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.
8. Welch S., Spithoff K., Rumble R.B., et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010, 21:1152-1153.
9. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003. (). Publish Date: December 12; 2003. http://ctep.cancer.gov/.
10. Parmar M.K.B., Torri V., Steward L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
11. Cochrane Collaboration (2004) RevMan user guide. Available from URL: [accessed 21 Dec 2007]. http://www.ccims.net/download/revman/Documentation/User%20guide.pdf.
12. Higgins JPT, Green S. Adverse effects for clinical trials. In: Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration; 2008.
13. Kabbinavar F.F., Hurwitz H.I., Yi J., et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009, 27:199-205.
14. Saltz L.B., Lenz H.J., Kindler H.L., et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007, 25:4557-4561.
15. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
16. Emmanouilides C., Pegram M., Robinson R., et al. Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech Coloproctol 2004, 8(Suppl. 1):s50-s52.
17. Kozloff M.F., Sungrue M.M., Purdie D.M., et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
18. Arnold D., Hinke A., Reinacher-Schick A.C., et al. Waterfall plot analysis of XELOX or XELIRI with cetuximab or bevacizumab in patients with advanced colorectal cancer (ACRC): combined analysis of two randomized first-line phase II trials of the AIO CRC study group. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
19. Gruenberger T., Kaczirek K., Bergmann M., et al. Progression-free survival in a phase II study of perioperative bevacizumab plux XELOX in patients with potentially curable metastatic colorectal cancer. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
20. Purdie D.M., Berlin J.D., Flynn P.J., et al. The safety of long-term bevacizumab use: results from the BRiTE observational cohort study (OCS). Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
21. Flynn P.J., Sugrue M.M., Purdie D.M., et al. Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: results from the BRiTE observational cohort study (OCS). Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
22. Sugrue M.M., Purdie D.M., Feng S., et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS). Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
23. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
24. Hochster H.S., Hart L.L., Ramanathan R.K., et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008, 26:3523-3529.
25. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835.
26. Emmanouilides C., Sfakiotaki G., Androulakis N., et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007, 7:91.
27. Giantonio B.J., Levy D.E., O'dwyer P.J., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006, 17:1399-13403.
28. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006, 24:3354-3360.
29. Berry S.R., Van Cutsem E., Kretzschmar A., et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEAT. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
30. Falcone A., Masi G., Loupakis F., et al. FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): a phase II study by the G.O.N.O. group. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
31. Moehler M, Sprinzl M.F., Abdelfattah M., et al. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009, 15:449-456.
32. Sobrero A., Ackland S., Clarke S., et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009, 77:113-119.
33. Venook A.P., Blanke C.D., Niedzwiecki D., et al. Cancer and leukemia group B/southwest oncology group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer 2005, 5:292-294.
34. Cunningham D., Wong R.P., D'haens G., et al. A phase II, double blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
35. Lembersky B.C., Sehgal R., Rajasenan K.K., et al. Phase II study of bevacizumab (BEV), weekly (wkly) intermittent capecitabine (Cap), and oxaliplatin (Ox) on an every-2-week schedule for patients (Pts) with untreated advanced colorectal cancer (CRC). Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
36. Bendell J.C., Uronis H.E., Morse M.A., et al. Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV) and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC). Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
37. Crane C.H., Eng C., Feig B.W., et al. Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer. Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
38. Cassidy J., Clarke S., Díaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
39. Tol J., Koopman M., Rodenburg C.J., et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008, 19:734-738.
40. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007, 25:4779-4786.
41. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502-3508.
42. Reinacher-Schick A.C., Kubicka S., Freier W., et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). Proceedings of the 44th America society of clinical oncology annual meeting, May 30-June 3 2008.
43. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
44. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
45. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
46. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
47. Tebbutt N.C., Wilson K., Gebski V.J., et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX study. J Clin Oncol 2010, 28:3191-3198.
48. Morere J.F., Des Guetz G., Mourad J., et al. Mechanism of bevacizumab-induced arterial hypertension: relation with skin capillary rarefaction in patients treated for metastatic colorectal cancer. J Clin Oncol 2007, 25(18S):3557.
49. Veronese M.L., Mosenkis A., Flaherty K.T. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24:1362-1369.
50. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 2006, 24(18S):3536.
51. Scartozzi M., Galizia E., Chiorrini S., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009, 20:227-230.
52. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
53. De Stefano A., Cannella L., Carlomagno C., et al. Correlation between bevacizumab-related hypertension and response in mCRC patients. ASCO Annual Meeting Proceedings. J Clin Oncol 2010, 28:15s. [suppl; abstr 3581].
54. Kozloff M.F., Berlin J., Flynn P.J., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78:329-339.
55. Hambleton J., Skillings J., Kabbinavar F., et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC), ASCO Annual Meeting Proceedings. J Clin Oncol 2005, 23(Suppl.):3554.
56. Hambleton J., Novotny W.F., Hurwitz H., et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004, 22(Suppl.):3528.
57. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
58. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.